This histogram enumerates side effects from a completed 2022 Phase 3 trial (NCT02005471) in the Venetoclax + Rituximab ARM group. Side effects include: Neutropenia with 61%, Diarrhoea with 39%, Nausea with 21%, Upper respiratory tract infection with 21%, Fatigue with 18%.
1 Treatment Group
Treatment (decitabine, venetoclax)
1 of 1
400 Total Participants · 1 Treatment Group
Primary Treatment: Venetoclax · No Placebo Group · Phase 2
Treatment (decitabine, venetoclax)Experimental Group · 3 Interventions: Decitabine, Venetoclax, Laboratory Biomarker Analysis · Intervention Types: Drug, Drug, Other
Drug Approval Stage
How many patients have taken this drug
Screening: ~3 weeks
Reporting: up to 5 years
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
12,990 Previous Clinical Trials
41,298,488 Total Patients Enrolled
1,478 Trials studying Leukemia
378,256 Patients Enrolled for Leukemia
M.D. Anderson Cancer CenterLead Sponsor
2,779 Previous Clinical Trials
1,784,363 Total Patients Enrolled
437 Trials studying Leukemia
31,990 Patients Enrolled for Leukemia
Marina KonoplevaPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
33 Total Patients Enrolled
2 Trials studying Leukemia
33 Patients Enrolled for Leukemia
Abhishek Maiti, MBBSPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
62 Total Patients Enrolled
1 Trials studying Leukemia
62 Patients Enrolled for Leukemia
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
Elderly patients with newly diagnosed AML, BPDCN, or MPAL not eligible for intensive chemotherapy.
You have AML or BPDCN with a history of MDS or CMML and are eligible for treatment at the time of diagnosis of AML regardless of any prior therapy for MDS or CMML.
You have a performance status of 0, 1, 2, or 3.
You have adequate renal function including creatinine < 2.0 unless related to the disease.
ALT < 3 x ULN unless considered due to leukemic involvement.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.